Karyopharm, maker of selinexor (XPOVIO) used in myeloma treatment has donated 60,000 medical masks in partnership with the Myeloma Crowd, Family Reach and the Leukemia & Lymphoma Society. The initiative will support some of the most vulnerable individuals impacted by the ongoing COVID-19 pandemic through the three patient-focused organizations.
The Myeloma Crowd will distribute the free masks to verified multiple myeloma, MGUS and smoldering myeloma patients. This generous gift by Karyopharm will help myeloma patients take necessary precautions as they continue to protect their health with procedures they are already familiar with - masking, handwashing, extra disinfection, social distancing and avoiding unecessary trips.
To receive the free masks, please do the following:
The Myeloma Crowd will also be distributing the masks to myeloma facilities in dire need of PPE.
“With often already compromised immune systems, patients with cancer are one of the most at-risk groups to be impacted by the ongoing COVID-19 pandemic,” said Sharon Shacham, PhD, MBA, President and Chief Scientific Officer of Karyopharm. “As a trusted partner within the cancer care community across the U.S., as well as a leader in the healthcare ecosystem based in Massachusetts, Karyopharm is pleased to be partnering with three amazing patient-centric organizations to help improve the safety of cancer patients, their families, and supporting healthcare workers.”
The Myeloma Crowd is excited to partner with Karyopharm on this initiative to deliver necessary and life-saving personal protection equipment to patients, their families, and healthcare providers. We are impressed with Karyopharm's dedication to improving the lives of patients battling multiple myeloma and other cancers. We hope that together we can continue to help improve the health outcomes for those impacted by this common form of blood cancer during the COVID-19 pandemic.
Karyopharm has also opened a clinical trial for all COVID-19 patients using low dose selinexor to combat the severe inflammatory response seen by those hospitalized. Selinexor may also have anti-viral properties to combat the virus. This clinical trial is currently enrolling patients from across the U.S., Europe, and Israel.
about the author
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.
Copyright © 2021 HealthTree Foundation. All Rights Reserved.
The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811